_
BackLink to: Home PageLink to: General Schedule of EventsLink to: Plenary SessionsLink to: Mini SymposiaLink to: Poster SessionsLink to: TSA Research FestivalLink to: NIH Job Fair for Postdoctoral FellowsLink to: Scheduled VendorsLink to: Special Exhibits and EventsLink to: Research Festival Committee"2000"-link to home page
NIH RESEARCH FESTIVAL October 10-13, 2000
Plenary Session 2

Wednesday, October 11
10:30 am - 12:00 pm
Plenary Session 2
- Masur Auditorium, CC

ANGIOGENESIS: MOLECULAR MECHANISMS AND THERAPEUTIC APPROACHES
William Stetler-Stevenson, NCI, Chair

Introduction
William G. Stetler-Stevenson

Angiogenesis is the development of new blood vessels in response to pathologic stimuli. Vasculogenesis is the process of blood vessel formation during embryonic development. The angiogenic response can function to potentiate the progression of the initiating pathology, e.g. tumor growth and spread during cancer progression, pannus formation in rhuematoid arthritis, diabetic retinopathy. In other disease states the growth of new vessels can compensate for diminished physiologic function, e.g. neoangiogenesis in response to occlusive vascular disease, wound healing , etc. NIH investigators are exploring the molecular mechanisms involved in vasculogenesis, as well as the initiation and regulation of angiogenic response and in various disease processes, with the aim of developing new therapeutic strategies for both promoting and inhibiting angiogenesis. This session will provide a brief overview of ongoing, intramural investigations on these mechanism, therapeutic strategies and preclinical development of therapies aimed at regulation of angiogenesis and vascular formation.

Role of Thymosin Beta 4 in Wound Healing
Hynda Kleinman, NIDR

Vasostatin, an Angiogenesis Inhibitor that Inhibits Tumor Growth
Giovana Tosato, CBER/FDA, and NCI

What Guides Blood Vessel Formation during Development: Fishing for Some Answers
Brant Weinstein, NICHD

Antiangiogenic Gene Therapy Approaches
Steve Libutti, NCI

Angiogenesis and Matrix Metalloproteinase Inhibitors:Preclinical and Clinical Development
William D. Figg, NCI

  top